| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1127455194 |
| P356 | DOI | 10.1007/S00277-020-03996-6 |
| P932 | PMC publication ID | 7203544 |
| P698 | PubMed publication ID | 32382770 |
| P2093 | author name string | Je-Hwan Lee | |
| Sung-Han Kim | |||
| Kyoo-Hyung Lee | |||
| Jiwon Jung | |||
| Jun Hee Woo | |||
| Sang-Ho Choi | |||
| Sang-Oh Lee | |||
| Yang Soo Kim | |||
| Yong Pil Chong | |||
| Jung-Hee Lee | |||
| Min Jae Kim | |||
| Jeongsoo Lee | |||
| Eun-Ji Choi | |||
| Han-Seung Park | |||
| P2860 | cites work | Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies | Q26853131 |
| Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections | Q33714717 | ||
| A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo | Q33936520 | ||
| Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review | Q36386176 | ||
| Efficacy of oral ribavirin in hematologic disease patients with paramyxovirus infection: analytic strategy using propensity scores. | Q36558322 | ||
| Parainfluenza virus lower respiratory tract disease after hematopoietic cell transplant: viral detection in the lung predicts outcome | Q37726073 | ||
| DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center | Q39976864 | ||
| A risk-adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with oral ribavirin therapy: A pilot study. | Q40055495 | ||
| Successful Treatment of Parainfluenza Virus Respiratory Tract Infection With DAS181 in 4 Immunocompromised Children | Q41103203 | ||
| Oral ribavirin for treatment of respiratory syncitial virus and parainfluenza 3 virus infections post allogeneic haematopoietic stem cell transplantation | Q42279293 | ||
| Human parainfluenza virus infection after hematopoietic stem cell transplantation: risk factors, management, mortality, and changes over time | Q42325543 | ||
| Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study | Q43848095 | ||
| The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation | Q45360414 | ||
| Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome | Q45736390 | ||
| Respiratory virus infections in bone marrow transplant recipients: the European perspective | Q45741856 | ||
| Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience | Q45741859 | ||
| Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. | Q50588456 | ||
| Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients | Q57053281 | ||
| Oral versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplantation Recipients | Q59352908 | ||
| Risk Factors for Parainfluenza Virus Lower Respiratory Tract Disease after Hematopoietic Cell Transplantation | Q59353822 | ||
| Respiratory Virus Infections in Hematopoietic Cell Transplant Recipients | Q61449841 | ||
| P577 | publication date | 2020-05-07 | |
| P1433 | published in | Annals of Hematology | Q15766509 |
| P1476 | title | Immunodeficiency risk score for prediction of mortality by parainfluenza virus infection in patients with hematologic malignancy |
Search more.